Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $437 from $441 and keeps a Hold rating on the shares. The firm updated its model ahead of Q1 results to reflect management commentary on quarterly growth trends, namely decreasing our 1Q CF revenue assumptions to reflect more seasonality than previously assumed.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Director Upadhyay to Step Down Amid CFO Move
- Vertex: Crowded IgAN Market and Gradual Povetacicept Adoption Keep Rating at Hold, Price Target Unchanged at $441
- Trump names Erica Schwartz CDC Director
- Vertex Pharmaceuticals: Solid CF Franchise and Emerging Pipeline Support Buy Rating and Premium Valuation
- Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley